GLI1-IN-1_product_DataBase

Bioactivity	GLI1-IN-1 (CBC-1) is a GLI-1 inhibitor with excellent water solubility and anticancer activity. GLI1-IN-1 can induce apoptosis and suppress the growth of colorectal cancer by inhibiting the Hedgehog(HH) (IC50=1.3 μM) pathway[1].
Target	IC50: 1.3 μM (Hedgehog).
Invitro	GLI1-IN-1 (CBC-1) (5-40 μM; 24-48 h) 具有抗癌活性，在 HT-29, SW-480 和 HCT-116 细胞中通过抑制 HH 通路的 mRNA 和蛋白表达来抑制细胞增殖，IC50 值分别为 7.13、15.31、3.33 μM。GLI1-IN-1 (5-40 μM; 24 h) 可以诱导 HT-29 细胞凋亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> GLI1-IN-1 相关抗体: Apoptosis Analysis[1] Cell Line:
In Vivo	GLI1-IN-1 (CBC-1) (50 mg/kg; 腹腔注射; 一天一次连续 16 天) 在 BALB/c/nu/nu 裸鼠中可以有效抑制异种移植物模型中的肿瘤生长，肿瘤抑制率为 68%[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2923907-92-8
Formula	C42H60N2O9
Molar Mass	736.93
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Chen J, et al. CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1. Steroids. Published online April 11, 2024.

PeptideDB